Navigation Links
MannKind Corporation Reports First Quarter Financial Results
Date:5/5/2008

- Conference Call Today at 5:00 p.m. EDT -

VALENCIA, Calif., May 5 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2008.

For the first quarter of 2008, total operating expenses were $74.1 million, compared to $77.3 million for the first quarter of 2007. Research and development (R&D) expenses decreased by $5.3 million to $58.4 million for the first quarter of 2008 compared to the first quarter of 2007, primarily due to lower clinical trial costs and associated packaging costs for clinical materials, partially offset by higher stock compensation expense. General and administrative (G&A) expenses increased by $2.1 million to $15.6 million for the first quarter of 2008 compared to the first quarter of 2007 primarily due to additional patent expenses.

The net loss applicable to common stockholders for the first quarter of 2008 was $71.4 million, or $0.70 per share based on 101.4 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $73.1 million, or $1.00 per share based on 73.4 million weighted average shares outstanding for the first quarter of 2007.

Cash and cash equivalents were $269.1 million at March 31, 2008 and $368.3 million at December 31, 2007.

Conference Call

MannKind management will host a conference call to discuss these results today at 5:00 p.m. EDT. To participate in the call, please dial (800) 857-0373 or (210) 839-8507. To listen to the call via the internet, please visit http://www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (866) 457-6651 or (203) 369-1300.

Presenting from the Company will be:

-- Chairman and Chief Executive Officer Alfred Mann

-- President and Chief Operating Officer Hakan Edstrom

-- Corporate Vice President and Chief Financial Officer Matthew Pfeffer

-- Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.

(Tables to follow)

MannKind Corporation

Condensed Statements of Operations

(Unaudited)

(in thousands, except per share amounts)

Three Months Ended March 31,

2008 2007

Revenue $20 $10

Operating expenses:

Research and development 58,445 63,788

General and administrative 15,640 13,550

Total operating expenses 74,085 77,338

Loss from operations (74,065) (77,328)

Other income 60 52

Interest expense on senior convertible

notes (337) (1,145)

Interest income 2,921 5,280

Loss before provision for income taxes (71,421) (73,141)

Income taxes - -

Net loss applicable to common

stockholders $(71,421) $(73,141)

Net loss per share applicable to common

stockholders - basic and diluted $(0.70) $(1.00)

Shares used to compute basic and diluted

net loss per share applicable to common

stockholders 101,409 73,388

MannKind Corporation

Condensed Balance Sheets

(Unaudited)

(in thousands)

March 31, December 31,

Assets 2008 2007

Current assets:

Cash and cash equivalents $269,079 $368,285

State research and development tax credit

exchange receivable - current - 831

Prepaid expenses and other current assets 8,004 9,596

Total current assets 277,083 378,712

Property and equipment - net 185,895 162,683

State research and development tax credit

exchange receivable - net of current portion 1,875 1,500

Other assets 549 548

Total $465,402 $543,443

Liabilities and Stockholders' Equity

Current liabilities $55,447 $67,558

Other liabilities - 24

Senior convertible notes 111,882 111,761

Stockholders' equity 298,073 364,100

Total $465,402 $543,443


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... (PRWEB) , ... April 18, 2017 , ... A number ... advances. This webinar, which is part of the Protein and Cell Analysis Education ... and outline where this technology fits in current and future applications. , Many ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today announced that ... after the company changed focus to making analytical tools for biopharmaceutical quality control. ... technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson ...
(Date:4/19/2017)... ... April 19, 2017 , ... ... financing round. This event adds to several other early achievements at ThermaGenix, including ... Scientific Teams. , ThermaGenix will use proceeds from the Series A-1 ...
(Date:4/19/2017)... ... April 19, 2017 , ... As part of ... accessible to novices as well as experienced users, attendees will gain a better ... screening tests. , Hemostasis testing quality is determined by preanalytical variables which ...
Breaking Biology Technology:
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
Breaking Biology News(10 mins):